May 17, 2020

Harris Healthcare confirms purchase of Iatric Systems

healthcare
Iatric
Technology
US
Sean Galea-Pace
2 min
The US-based company, Harris Healthcare, has announced it has purchased Iatric Systems for an undisclosed fee, mobi health news reports.

Officials have...

The US-based company, Harris Healthcare, has announced it has purchased Iatric Systems for an undisclosed fee, mobi health news reports.

Officials have confirmed that Iatric, which focuses on integration tools in order to aid hospitals to optimise their electronic health records and other IT infrastructure, will now run as a separate business unit of Harris.

The Boxford-based company, Iatric, creates a range of technology that is utilised for security, interoperability, medical device connectivity as well as other areas of HER optimisation.

Harris Healthcare President Jerry Canada Jr, said: “The acquisition of Iatric Systems represents a natural extension of our offerings in the healthcare information technology segment.”

See more:

It has also been revealed that Iatric President and Chief Operating Officer, Frank Fortner, has been named the new Executive Vice President for Iatric Systems.

In a press release, Mr Fortner said: “This investment is a tremendous vote of confidence in our team and technology.”

“We are pleased to become part of the Harris family of companies. This positions Iatric Systems well for continued and long-term success with our 28-year history of providing innovative healthcare IT solutions to hospitals and healthcare systems.”

Share article

Jul 28, 2021

5 mins with... Johannes Bhakdi, Quantgene

COVID19
Genomics
AI
biotechnology
3 min
5 mins with... Johannes Bhakdi, Quantgene
Johannes Bhakdi, CEO of Quantgene, tells us about their approach to identifying new COVID-19 variants

Quantgene is a US biotech company that uses AI and the cloud to do genomic testing. It was founded in 2015 to focus on cancer - integrating advanced genomics and molecular diagnostics systems with the cloud and AI systems. 

CEO Johannes Bhakdi tells us Quantgene is the first COVID-19 testing company to fully integrate variant identification - we find out more. 

Given the new Delta and Lambda variants, is the coronavirus mutating at a faster rate than most viruses?
 
The reason SARS-COV2 is mutating on a perceived higher rate is not that the individual viruses mutate at a higher rate, but that the base population infected with the virus is vastly higher. The absolute rate of global mutations is a direct function of how many people have the virus at any given point in time. Since this is a global pandemic, and tens of millions have been infected, we see more mutations. 

That makes it more unpredictable, because any single mutation that has an evolutionary advantage - like the Delta variant - can then take over and spread even faster.  

What is the usual process for testing and analysing viral mutations? 

The most effective tool for analysing mutations is Whole Viral Genome sequencing. It allows you to read out the entire genome of the virus. Once the wet-lab sequencing is complete, we use this information to map it against what is called a "reference genome", meaning the classic SARS-COV2 genome. This allows us to then see any differences between the investigated sample and the baseline genome of SARS COV2. 

We then use these differences to map them against a database of known mutations, like the Delta variant. That way we can see if we are dealing with any known variant, and if we have a new variant at our hands, as well as determine what this new variant does to the spike protein and how likely it is to be a problem with antigens and vaccines, based on the changed protein structure. This last step is not easy and not clear-cut, and there is some speculation into the determination of how problematic the mutated proteins are. 

 What does Quantgene do differently?  

At Quantgene, we are focusing on solving problems for our clients - may it be employers, movie productions or governments. That means we ensure that our client gets the COVID protection they need in the fastest possible time frame and at the highest precision possible - mostly at or below market prices. 

We are bringing together technologies like RT-PCR testing and mutation profiling/sequencing, as well as advanced bioinformatics and computational resources to ensure high-quality results are being delivered seamlessly. 

We are also adding important components such as real-time cloud software and medical services to it. Simply put, we turn the COVID problem into a one-click seamless solution that works better than others, so companies and government clients don't have to deal with laboratories, medical or software providers who point fingers at each other and fail to deliver in time and with high precision. COVID is too dangerous and important to risk falling short.     

Share article